Press releases

• Friday, 08 November 2002

  5-ASAs/mesalazine May Lower Colorectal Cancer Risk in Inflammatory Bowel Disease (IBD)

• Thursday, 31 October 2002

  Ferring Pharmaceuticals and Beth Israel Deaconess Medical Center Announce Drug Discovery Collaboration Agreement

• Wednesday, 30 October 2002

  Ferring and Johnson & Johnson Join in a Research Collaboration

• Wednesday, 02 October 2002

  Ferring appoints new Board member

• Tuesday, 01 October 2002

  Ferring Appoints New Vice-President of Global Marketing

• Thursday, 16 May 2002

  Taking the Needle Out of the Injection

• Monday, 13 May 2002

  Ferring Appoints New Board Member

• Monday, 06 May 2002

  FDA APPROVES BRAVELLE™ (urofollitropin for injection, purified)

• Thursday, 21 March 2002

  Building for the 21st Century

• Wednesday, 23 January 2002

  Advances In Infertility

• Tuesday, 08 January 2002

  New Ferring International Center opens for business

Corporate Communications

Ferring International Center S.A.
Ch. de la Vergognausaz 50
CH-1162 Saint-Prex
Switzerland
Tel: +41 58 301 00 00
Fax: +41 58 301 00 10

Email for media enquiries only.
For other queries, please see our Contact page.